Countries such as Sweden that have a low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) offer the opportunity to discern and study transmission of imported cases of MRSA. We analyzed 444 imported cases of MRSA acquisition reported in Sweden during 2000–2003. Risk for MRSA in returning travelers ranged from 0.1 (95% confidence interval [CI] 0.01–0.4) per 1 million travelers to Nordic countries to 59.4 (95% CI 44.5–79.3) per 1 million travelers to North Africa and the Middle East. Most imported cases (246, 55%) were healthcare acquired, but regions with the highest risk for MRSA in travelers showed a correlation with community acquisition ($r = 0.81$, $p = 0.001$). Characteristic differences in MRSA strains acquired were dependent on the region from which they originated and whether they were community or healthcare acquired. Knowledge of differences in transmission of MRSA may improve control measures against imported cases.

Global transmission of methicillin-resistant Staphylococcus aureus (MRSA) has been the subject of many studies. Conclusions have commonly been drawn from the occurrence of identical or similar strains in different countries or regions (7–11). Only a few small analytical or population-based studies have been published (12–14). In countries with a high prevalence of MRSA, imported cases of MRSA are not easily distinguished from the domestic background prevalence. Thus, low prevalence countries, such as Sweden, offer a better opportunity to discern and study imported cases of MRSA.

The primary purpose of our study was to use validated data from the surveillance system in Sweden to analyze the risk for MRSA among Swedish residents traveling abroad, internationally adopted children, and immigrants. A secondary purpose was to determine whether different types of MRSA were acquired in different countries or regions.

Materials and Methods

Data on MRSA Cases in the Statutory Swedish Communicable Disease Notification System

The study was reviewed and approved by the Regional Ethics Approval Board in Stockholm (Protocol 2005/4:10). MRSA cases (infections as well as carriage) are notified in parallel to the Swedish Institute for Infectious Disease Control (SMI) by the doctor caring for the patient and by the bacteriological laboratory having isolated the MRSA strain, using a unique personal identification number issued to all Swedish residents and used in all contacts with the health care system. At SMI, a case record is created after the arrival of the first notification. Any subsequent notifications are merged with the initial case record. After completion of the epidemiologic investigation and contact tracing around each MRSA case, the epidemiologic notification form data are validated by SMI with input from MRSA contact persons, who are public health representatives involved in control efforts locally.
in the respective counties (15). The validated variables used in the study were age, sex, transmission setting (healthcare acquired [HA] or community acquired [CA]), country of acquisition, and purpose of travel (leisure or work related) (16). If a person infected with MRSA had been abroad ≤6 months before MRSA was diagnosed and either had a strain that was present in other persons from that region or had one that was previously unknown in Sweden and no likely source of MRSA in Sweden was found in the epidemiologic investigation, that person was considered to have acquired MRSA abroad. If there was a reasonable possibility that MRSA could have been acquired either domestically or abroad, country of acquisition was considered unknown. If the person infected with MRSA had been admitted to or had worked in a healthcare setting during his or her stay abroad, he or she was considered to have a case of HA MRSA. Information in the study database on whether a person had MRSA disease or MRSA carriage was based on clinical case data from the physician caring for the patient.

For additional analysis, the reported cases of MRSA were divided into the following categories: residents of Sweden traveling abroad for recreational purposes, residents of Sweden traveling abroad because of work or studies, foreign residents traveling to Sweden for a temporary visit, immigrants, internationally adopted children, or Swedish citizens returning home after having lived abroad for >1 year. The risk for MRSA in travelers, immigrants, and people of Sweden traveling abroad for work or study reasons (leisure or work) (17). Statistical Analysis

Stata 8.2 software (StataCorp LP, College Station, TX, USA) was used for all statistical analyses, and a 95% level of significance was applied. Sex, age group, purpose of travel, and destination were used as explanatory variables in multivariable analysis of travelers with a diagnosis of MRSA and its reporting as an outcome. Generalized estimating equations with independent correlation and robust standard errors were used to enable clustering of data in the adjusted model that included all travelers <75 years of age.

Results

During 2000–2003, a total of 1,733 cases of MRSA were reported in Sweden, 444 of which were considered to have been acquired abroad. Among these imported cases, 292 (65.8%) were in residents of Sweden who traveled abroad; 31 (7.0%) had traveled for work reasons or studies. Fifty-six (12.6%) of the cases were in newly arrived immigrants to Sweden, 40 (9.0%) in internationally adopted children from non-Nordic countries, 30 (6.8%) in temporary residents of Sweden, 20 (4.5%) in citizens of Sweden returning home after having lived abroad for >1 year, and 6 (1.4%) in persons who could not be grouped. Of the imported MRSA cases, 246 (55.4%) were HA and 146 (32.9%) were CA; 190 (42.8%) were in persons with MRSA disease.

MRSA in Travelers Returning to Sweden

Of the 292 residents of Sweden who traveled abroad, 267 met the age criteria and were included in this analysis.

Data on Immigration and International Adoptions

Denominator data on the yearly number of immigrants to Sweden were obtained from Statistics Sweden (18). Included in the immigration figures were persons who received a residence permit because of family ties, European Economic Area convention, and labor permits; visiting students; and asylum seekers per country of citizenship. Data on the yearly number of international adoptions per country were obtained from the Swedish Intercountry Adoptions Authority (19).

Epidemiologic Typing of MRSA Isolates

Isolates from all persons with new cases of MRSA were sent to SMI, where laboratory diagnosis of MRSA was confirmed by using PCR for the mecA and the nuc genes (20). Epidemiologic typing of all isolates was performed by using pulsed-field gel electrophoresis (PFGE) according to the protocol of Murchan et al. (21). On the basis of PFGE results, representative isolates were selected for multilocus sequence typing (MLST) (22), and sequence types (STs) of isolates were determined by using the MLST database (www.mlst.net).

Swedish Tourist and Travel Database

Travel data from the commercial Swedish Tourist and Travel Database (TDB) were used as a denominator when analyzing the risk for being reported as having MRSA in travelers from Sweden. The TDB is based on monthly interviews with 2,000 randomly selected residents of Sweden. We used the TDB variables age group, sex, purpose of travel (leisure or work), main destination, and time of travel. TDB for 2000–2003 and interviews of 9,213 persons with a history of travel abroad were used. Information in the TDB was weighted and extrapolated to estimate the total number of travelers from Sweden and to derive a total of 45,855,000 travel episodes (17). Actual interviewees were used as controls in an adjusted model that estimated the odds ratio (OR) of having MRSA, and extrapolated estimates were used to calculate risks per 1,000,000 travelers. Because only persons <75 years of age were sampled for interviews for the TDB, 34 cases of MRSA in persons >74 years of age were excluded from the TDB analyses.

Statistical Analysis

Stata 8.2 software (StataCorp LP, College Station, TX, USA) was used for all statistical analyses, and a 95% level of significance was applied. Sex, age group, purpose of travel, and destination were used as explanatory variables in multivariable analysis of travelers with a diagnosis of MRSA and its reporting as an outcome. Generalized estimating equations with independent correlation and robust standard errors were used to enable clustering of data in the adjusted model that included all travelers <75 years of age.
Most persons with MRSA had traveled to Thailand (n = 33), the United Kingdom (n = 24), Greece (n = 22), the former Yugoslavia (n = 20), Lebanon (n = 16), the United States (n = 14), Cyprus (n = 12), Spain (n = 12), Turkey (n = 9), and Syria (n = 8). The overall risk for being reported as having MRSA was 5.8 cases/1,000,000 travelers (95% confidence interval [CI] 5.2–6.6). The crude risk for travelers to specific regions ranged from 0.1 (95% CI 0.01–0.4) per 1,000,000 travelers to Nordic countries to 59.4 (95% CI 44.5–79.3) per 1,000,000 travelers to North Africa and the Middle East (Table 1). Rank in risk for MRSA in the regions analyzed changed only slightly when we adjusted for confounders.

The adjusted OR for having MRSA was 1.5× higher among male participants (95% CI 1.2–2.0) than female participants (Table 1). The crude risk differed slightly between age groups and was highest among persons 60–74 years of age (11 cases/1,000,000 travelers; 95% CI 8.1–13.8), but no difference was found in the OR between age groups in the adjusted model. Work-related travel showed a lower crude risk for being reported as having MRSA, but when adjusting for other risk factors, the OR of MRSA was 2.4× higher among persons who traveled for work purposes than in leisure travelers (95% CI 1.5–3.8). To examine to what degree inclusion or exclusion of carriers would change our findings, analysis was repeated by using only the 133 (49.8%) cases in travelers with MRSA disease. We found only minor changes in ranking of ORs for geographic regions. The same 5 regions (Table 1) still ranked highest with higher ORs than other regions. The most prominent difference for ORs was that South America and Oceania and Pacific Islands changed places in rank.

Percentages of CA-MRSA for the respective regions, correlated linearly with adjusted ORs (r = 0.81, p = 0.001). Among age groups, the proportion of cases of CA-MRSA was highest in persons 0–14 years of age (83.3%), lowest in persons 60–74 years of age (9.3%), and intermediate for other age groups.

### Table 1. Estimated number of travelers and cases of travel-associated acquisition of MRSA, Sweden, 2000–2003*

| Variable | Estimated no. travelers | No. with MRSA infection (no. with MRSA disease) | Crude risk/1 million travelers (95% CI) | % Community-acquired cases | Adjusted OR (95% CI) |
|----------|-------------------------|-----------------------------------------------|----------------------------------------|---------------------------|---------------------|
| **Sex**  |                         |                                               |                                        |                           |                     |
| F        | 25,219,000              | 109 (62)                                      | 4.3 (3.6–5.2)                          | 42.2                      | Reference           |
| M        | 20,634,000              | 158 (71)                                      | 7.7 (6.6–8.9)                          | 27.2                      | 1.5 (1.2–2.0)       |
| **Age group, y** |                                 |                                               |                                        |                           |                     |
| 0–14     | 6,497,000               | 30 (24)                                       | 4.6 (3.2–6.6)                          | 83.3                      | Reference           |
| 15–29    | 8,657,000               | 72 (36)                                       | 8.3 (6.6–10)                           | 31.9                      | 1.0 (0.6–1.5)       |
| 30–44    | 13,234,000              | 49 (26)                                       | 3.7 (2.8–4.9)                          | 44.9                      | 0.8 (0.5–1.3)       |
| 45–59    | 12,342,000              | 62 (29)                                       | 5.0 (3.9–6.4)                          | 22.6                      | 0.8 (0.5–1.2)       |
| 60–74    | 5,127,000               | 54 (18)                                       | 11 (8.1–13.8)                          | 9.3                       | 1.2 (0.7–1.9)       |
| **Purpose of travel** |                                 |                                               |                                        |                           |                     |
| Leisure  | 36,323,000              | 237 (123)                                     | 6.5 (5.7–7.4)                          | 34.2                      | Reference           |
| Work     | 9,532,000               | 30 (10)                                       | 3.1 (2.2–4.5)                          | 26.7                      | 2.4 (1.5–3.8)       |
| **Region of origin†** |                                 |                                               |                                        |                           |                     |
| Nordic   | 15,962,000              | 1 (0)                                         | 0.1 (0.01–0.4)                         | 0.0                       | 0.1 (0.01–0.6)      |
| Western Europe | 7,614,000               | 7 (3)                                         | 0.9 (0.4–1.9)                          | 14.3                      | Reference           |
| Southern Europe | 7,601,000               | 18 (5)                                        | 2.4 (1.5–3.8)                          | 0.0                       | 2.4 (1.0–5.8)       |
| Central and Eastern Europe | 2,885,000               | 7 (5)                                         | 2.4 (1.2–5.1)                          | 28.6                      | 2.8 (1.0–8.1)       |
| UK and Ireland | 2,815,000               | 26 (11)                                       | 9.2 (6.3–13.6)                         | 7.7                       | 10.3 (4.4–24.0)     |
| North America | 1,627,000               | 17 (4)                                        | 10.4 (6.5–16.8)                        | 35.3                      | 10.6 (4.2–26.7)     |
| Northeastern Mediterranean | 4,317,000               | 63 (30)                                       | 14.6 (11.4–18.7)                       | 38.1                      | 15.8 (7.0–35.6)     |
| South America | 152,000                | 6 (5)                                         | 39.5 (17.7–87.9)                       | 33.3                      | 31.2 (10.0–97.6)    |
| East Asia | 1,622,000               | 54 (27)                                       | 33.3 (25.5–43.5)                       | 27.8                      | 36.5 (16.2–82.0)    |
| Oceania and Pacific Islands | 250,000                | 11 (5)                                        | 44.0 (24.4–79.5)                       | 36.4                      | 43.0 (15.5–119.4)   |
| Sub-Saharan Africa | 232,000                | 11 (7)                                        | 47.4 (26.3–85.6)                       | 54.5                      | 46.3 (17.3–123.6)   |
| North Africa and Middle East | 774,000                | 46 (31)                                       | 59.4 (44.5–79.3)                       | 58.7                      | 59.0 (25.1–138.9)   |

*MRSA, methicillin-resistant Staphylococcus aureus; CI, confidence interval; OR, odds ratio.
†Nordic: Denmark, Finland, Iceland, Norway; Western Europe: Austria, Belgium, France, Germany, Luxembourg, the Netherlands, Switzerland; Southern Europe: Italy, Malta, Monaco, Portugal, Spain; Central and Eastern Europe: Belarus, Bulgaria, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Poland, Romania, Russia, Slovakia, Czech Republic; Ukraine; North America: Canada, Cuba, Dominican Republic, Guadeloupe, Guatemala, Mexico, Panama, United States; Northeastern Mediterranean: Albania, Bosnia-Herzegovina, Cyprus, former Yugoslavia, Greece, Croatia, Macedonia, Serbia, Slovenia, Turkey; South America: Brazil, Chile, Colombia, Ecuador, Peru, Venezuela; East Asia: Afghanistan, Bangladesh, Cambodia, China, Hong Kong, India, Indonesia, Japan, South Korea, Malaysia, Maldives, Mongolia, Pakistan, Singapore, Sri Lanka, Taiwan, Thailand, Vietnam, the Philippines; Oceania and Pacific islands: Australia, Hawaii, New Zealand, Samoa; Sub-Saharan Africa: Angola, Botswana, Chad, Ethiopia, the Gambia, Ghana, Kenya, Congo–Kinshasa, Madagascar, Senegal, Sierra Leone–Togo, Somalia, Sudan, Swaziland, South Africa, Tanzania–Uganda; North Africa and Middle East: Algeria, Egypt, Iraq, Iran, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Saudi Arabia, Syria, Tunisia, United Arab Emirates.
MRSA in Immigrants

A total of 56 persons who had recently arrived in Sweden as immigrants had cases of MRSA (Table 2), giving an overall risk of 15.9 (95% CI 12.0–20.7) cases/100,000 immigrants. MRSA disease was present in 27 (48.2%) of the immigrants. Twenty of the persons with MRSA came from the former Yugoslavia. The highest number of immigrants (n = 45,587) also came from this country; these persons had a risk of 43.8 (95% CI 26.8–67.8) MRSA cases/100,000 immigrants. Nearly as many immigrants came from Iraq, but the risk for MRSA was lower for this group (9.1, 95% CI 2.5–23.4 cases/100,000 immigrants).

MRSA in Adopted Children

In 2000–2003, a total of 4,169 children were adopted from non-Nordic countries. Forty adopted children from 12 countries were reported as having cases of MRSA shortly after their arrival in Sweden, i.e., 9.6 (95% CI 6.9–13.0) cases per 1,000 adoptions (Table 3). Of these adopted children with MRSA, 6 had MRSA disease. Risk for having MRSA ranged from 3.0/1,000 adoptions of children from Vietnam (95% CI 0.1–16.8) to 74.1/1,000 adoptions of children from the Philippines (95% CI 9.1–242.8). The largest number of adopted children (n = 1,074) came from the People’s Republic of China. However, only 6.5/1,000 adoptees (95% CI 2.6–13.4) from this country had MRSA. Children adopted from South Korea showed 30.0 cases/1,000 adoptions (95% CI 16.5–49.8).

Type of MRSA and Geographic Region of Acquisition

STs inferred from PFGE results and region of acquisition for 414 MRSA cases (excluding secondary cases and cases with STs seen in <5 cases) are shown in the online Appendix Table (www.cdc.gov/EID/content/16/2/189-appT.htm). Also shown are the number of HA-MRSA and CA-MRSA cases per ST and region of acquisition. HA ST22 and ST36 predominated in cases from the United Kingdom and Ireland (15/33 and 11/33 MRSA cases, respectively). Among 92 cases from East Asia, the predominant MRSA were HA ST239 (n = 22 cases), CA ST30 (n = 13 cases), and CA ST72 (n = 6 cases). CA ST30 isolates were also seen in 5 cases from neighboring areas (3 from the Oceania and Pacific Islands region and 2 from Hawaii that belonged to North American region). Among the 50 cases from North Africa and the Middle East, CA ST80 (n = 18 cases) dominated. ST 80 was also isolated from 21 of 90 cases from the neighboring northeastern Mediterranean region. However, this region was mainly characterized by 30 HA ST239 (n = 30 cases). In cases from southern Europe, HA ST228 was most frequently seen (11/36 cases). Overall, STs 5, 22, 239, and 241 were found most often in cases of HA-MRSA, and STs 30 and 80 were found most often in

| Table 2. Imported cases of MRSA acquisition among immigrants, Sweden, 2000–2003* |
|---------------------------------|-----------------|-----------------|-----------------|
| Country of origin              | No. immigrants†| No. with MRSA acquisition | Risk/100,000 immigrants (95% CI) |
| Malta                           | 21              | 1 (0)            | 4,761.9 (120.5–23,816.9) |
| Kazakhstan                      | 933             | 4 (2)            | 428.7 (116.9–1,094.0) |
| South Africa                    | 556             | 2 (1)            | 359.7 (43.6–1,293.3) |
| Sudan                           | 360             | 1 (1)            | 277.8 (7.0–1,537.9) |
| Italy                           | 1,382           | 2 (1)            | 144.7 (17.5–521.8) |
| Ecuador                         | 995             | 1 (1)            | 100.5 (2.5–558.6) |
| Lebanon                         | 2,100           | 2 (0)            | 95.2 (11.5–343.6) |
| Mongolia                        | 1,055           | 1 (1)            | 94.8 (2.4–527.0) |
| Japan                           | 1,274           | 1 (0)            | 78.5 (2.0–436.2) |
| The Philippines                 | 1,335           | 1 (1)            | 74.9 (1.9–416.6) |
| Afghanistan                     | 6,166           | 4 (3)            | 64.9 (17.7–166.0) |
| United States                   | 4,094           | 2 (0)            | 48.9 (5.9–176.4) |
| Former Yugoslavia               | 45,587          | 20 (10)          | 43.8 (26.8–67.8) |
| Germany                         | 6,564           | 2 (0)            | 30.5 (3.7–110.0) |
| Poland                          | 3,658           | 1 (0)            | 27.3 (0.7–152.2) |
| Iran                            | 7,856           | 2 (1)            | 25.5 (3.1–91.9) |
| Thailand                        | 4,883           | 1 (0)            | 20.5 (0.5–114.0) |
| United Kingdom                  | 5,306           | 1 (0)            | 18.9 (0.4–77.0) |
| Turkey                          | 5,586           | 1 (1)            | 18.0 (0.5–100.0) |
| Russia                          | 8,254           | 1 (0)            | 12.1 (0.3–67.5) |
| Somalia                         | 8,546           | 1 (1)            | 11.7 (0.3–65.2) |
| Iraq                            | 43,730          | 4 (3)            | 9.1 (2.5–23.4) |
| Other countries                 | 191,302         | 0               | – |
| Total                           | 351,525         | 56 (27)          | 15.9 (12.0–20.7) |
*MRSA, methicillin-resistant Staphylococcus aureus; CI, confidence interval.
†Included in the immigration figures were persons who received a residence permit because of family ties, European Economic Area convention, and labor permits; visiting students; and asylum seekers per country of citizenship.
cases of CA-MRSA. Strains acquired in North America or European regions were associated with HA-MRSA.

Discussion
We have estimated risks for MRSA among travelers returning from specific geographic regions. Other studies have reported individual cases of MRSA diagnosed in connection with travel (10,11,23–25). Kaiser et al. (12) studied patients in the Netherlands who were repatriated after having received healthcare abroad, but found no association between country or region and MRSA diagnosis. However, the participation rate in their study was low, and the lack of statistically significant results could have been caused by the low number of cases.

The overall prevalence and transmission rate of MRSA within a country or region is just one of several factors that can influence the risk for MRSA acquisition by travelers to that country or region. This risk will also depend on type of exposure and duration of stay. For example, risk for MRSA acquisition will vary, depending on whether the person had received healthcare or had only community contacts, whether he or she stayed in a hotel at a holiday resort for a week, stayed with relatives for 3 months, or just stayed overnight on a business trip. In Europe, we observed a relatively high risk for MRSA acquisition in travelers to the United Kingdom, Ireland, and southern Europe, which is consistent with the high prevalence of MRSA reported for these regions (26–28). Other studies have shown that MRSA is hyperendemic to the Pacific region, East Asia, the Mediterranean region, and the Middle East (27–29). Thus, the higher risk for MRSA among travelers returning from these regions in our study may reflect such hyperendemicity. In addition, we found a higher risk for MRSA among travelers to sub-Saharan Africa and South America, and a risk for MRSA among travelers to central and eastern Europe that is comparable to that among travelers to southern Europe.

The risk for immigrants and adopted children of acquiring MRSA may not be representative of the overall risk in the general population in their respective countries of origin. These 2 populations may have spent time in institutional settings (e.g., orphanages, refugee camps, or hospitals) in which the risk for MRSA exposure may be different from that in the community in general. In addition, analysis of MRSA risk among newly adopted children and immigrants was based on small numbers of persons, which resulted in wide CIs of the estimated risks. Despite this uncertainty, agreement was seen between the estimated risk for MRSA acquisition among returning travelers, immigrants, and adopted children. Eight of 12 countries from which the adopted children with MRSA originated and 14 of the 22 countries from which immigrant cases originated belonged to the 6 regions with highest risk for MRSA among travelers (northeastern Mediterranean, South America, East Asia, Oceania and Pacific islands, sub-Saharan Africa, and North Africa and the Middle East).

Measuring the risk for MRSA in travelers, adopted children, and immigrants involved analyzing 3 different groups related to specified countries and regions. Because of the large degree of agreement between the 3 groups, results obtained may reflect not only risks for MRSA in these 3 populations, but also an overall comparatively higher risk for MRSA in some regions than in others.

The study was based on persons (carriers and those with clinical disease) with reported cases of MRSA in Sweden during 2000–2003. Only minor changes, which did not affect our primary findings, were seen when carrier cases were excluded from the travel analysis. Approximately 50% of MRSA cases among immigrants, but only 15% (6/40) of adopted children, had MRSA disease. Twelve of the 13 countries from which immigrants originated belonged to the 6 regions with highest risk for MRSA among travelers. For adopted children, the numbers of countries

Table 3. Imported cases of MRSA acquisition among children adopted from other countries, Sweden, 2000–2003*

| Country                  | No. adoptions | No. with MRSA acquisition | Risk/1,000 adoptions (95% CI) |
|--------------------------|---------------|----------------------------|-------------------------------|
| The Philippines          | 27            | 2 (0)                      | 74.1 (9.1–242.8)              |
| South Korea              | 467           | 14 (0)                     | 30.0 (16.5–49.8)              |
| Bulgaria                 | 91            | 2 (1)                      | 22.0 (2.7–77.1)               |
| Belarus                  | 174           | 3 (1)                      | 17.2 (3.6–49.6)               |
| Russia                   | 263           | 4 (0)                      | 15.2 (4.2–38.5)               |
| Ethiopia                 | 71            | 1 (1)                      | 14.1 (0.4–76.0)               |
| Ukraine                  | 74            | 1 (0)                      | 13.5 (0.3–73.0)               |
| People’s Republic of China | 1,074        | 7 (3)                      | 6.5 (2.6–13.4)                |
| Colombia                 | 460           | 3 (0)                      | 6.5 (1.3–18.9)                |
| South Africa             | 154           | 1 (0)                      | 6.5 (0.16–35.6)               |
| India                    | 243           | 1 (0)                      | 4.1 (0.1–22.7)                |
| Vietnam                  | 328           | 1 (0)                      | 3.0 (0.1–16.8)                |
| Other countries          | 743           | 0                          | –                             |
| Total                    | 4,169         | 40 (6)                     | 9.6 (6.9–13.0)                |

*MRSA, methicillin-resistant Staphylococcus aureus; CI, confidence interval.
involved and cases decreased when carriers were excluded. However, 2 of 4 countries (4 of 6 cases) still belonged to the same 6 regions. Results for these 3 populations with acquired MRSA are consistent even when carriers were excluded from the analysis.

One strength of our study is that all regions/countries were investigated by using the same surveillance system, thus avoiding problems that might arise when data for different countries are compiled from different sources. Because the travel analysis was based on residents of Sweden who traveled to other countries and results were adjusted for sex and age, the main conclusions should also be valid for other western countries. Possible biases related to MRSA cases reported in Sweden during 2000–2003 and use of the TDB have been evaluated (16,30). Information from the TDB has shown good agreement with data from other sources (31). We could not control for length of stay of travelers at their destination because such information for MRSA cases was not available. However, persons with cases of MRSA who traveled for work purposes were commonly employed at the destination for a few months, rather than having been on short business trips.

Most persons infected with MRSA had HA-MRSA; only 33% had CA-MRSA. However, CA-MRSA showed a strong correlation with regions with a high risk for MRSA among travelers. This finding might be caused by a higher propensity among clinicians to sample patients with a history of activity (e.g., backpacking) under less than optimal sanitary conditions or travel to exotic regions. The 5 regions with the highest OR of acquiring MRSA in adjusted analysis were outside Europe.

Geographic distribution of MRSA STs was consistent with that in studies of other regions. ST22 and ST36 are well documented in the healthcare system in the United Kingdom (32). ST80 is common in the Mediterranean and Balkan region, the Middle East, and several countries in Europe, and epidemiologically related to persons with direct or indirect contact with the Mediterranean and Middle East (1,11,12,23–25). ST239 is common Asia (33,34) and the northeastern Mediterranean (35); ST30 is common in the Pacific region, East Asia, and Oceania (1,36); and ST228 is common in southern Europe and Germany (37,38).

In addition to showing an association between specific STs and regions, we also identified the transmission setting (healthcare or community) in which the isolate was acquired. We observed that most STs among imported cases of MRSA were associated with either HA-MRSA or CA-MRSA. ST30 and ST80 were strongly associated with CA-MRSA. ST72 was identified only among 8 adopted children from South Korea. However, information for the orphanages was not available. Thus, the possibility that 8 children could have been part of the same local transmission chain could not be ruled out. However, ST72 has recently been reported from several areas of South Korea among children and as a community-associated sequence type (39,40).

Several limitations of our study involve factors relevant to MRSA acquisition (length of stay abroad, contacts with institutions with a higher probability of MRSA transmission such as healthcare settings, orphanages, or refugees camps) that were not measured. In addition, there may have been inconsistencies in how MRSA cases were selected in the surveillance system. In some counties in Sweden, MRSA screening of adopted children is conducted; in other counties, it is not practiced. Thus, underdiagnosis of MRSA carriage among adopted children was likely. No similar screening recommendations are known for newly arrived refugees or immigrants.

In countries with a low prevalence of MRSA, a larger proportion of cases are imported than in countries with a high prevalence of MRSA. The risk for additional domestic transmission indicates a greater need to focus public health measures toward these imported cases. We observed differences in risk for MRSA among travelers returning from different regions, adopted children, and immigrants. Risk estimates for MRSA measured in these 3 groups showed a consistent pattern; some regions showed a higher risk for acquiring MRSA. Although most imported cases of MRSA were HA-MRSA, community acquisition showed a correlation with regions that have a high risk for MRSA among travelers. Knowledge of these differences in risk for MRSA will improve control measures and decrease domestic transmission.

Acknowledgments
We thank Ann Lindmark and Maj Ringman for excellent laboratory work and Sharon Kühllmann-Berenzen for valuable statistical advice.

This study was supported by the Swedish Institute for Infectious Disease Control.

Dr Stenhem is a clinical specialist in infectious diseases in the Department of Epidemiology, Swedish Institute for Infectious Disease Control in Solna, Sweden. His research interest is infectious disease epidemiology, particularly disease surveillance and MRSA epidemiology.

References
1. Tristan A, Bes M, Meugnier H, Lina G, Bozdogan B, Courvalin P, et al. Global distribution of Panton-Valentine leukocidin-positive methicillin resistant Staphylococcus aureus, 2006. Emerg Infect Dis. 2007;13:594–600. DOI: 10.3201/eid1304.061316
2. Deplano A, Witte W, Van Leeuwen WJ, Brun Y, Struelens MJ. Clonal dissemination of epidemic methicillin-resistant Staphylococcus aureus in Belgium and neighboring countries. Clin Microbiol Infect. 2000;6:239–45. DOI: 10.1046/j.1469-0691.2000.00064.x
6. Townsend DE, Dickinson G, De Lancastre H, Tomasz A. International clones of methicillin-resistant *Staphylococcus aureus* in two hospitals in Miami, Florida. J Clin Microbiol. 2004;42:542–7. DOI: 10.1128/JCM.42.2.542-547.2004

5. da Silva Coimbra MV, Silva-Carvalho MC, Wisplinghoff H, Hall GO, Tallent S, Wallace S, et al. Clonal spread of methicillin-resistant *Staphylococcus aureus* in a large geographic area of the United States. J Hosp Infect. 2003;53:103–10. DOI: 10.1053/jhin.2002.1328

6. Townsend DE, Ashdown N, Bolton S, Bradley J, Duckworth G, Moorhouse EC, et al. The international spread of methicillin-resistant *Staphylococcus aureus*. J Hosp Infect. 1987;9:60–71. DOI: 10.1016/0195-6701(87)90097-1

7. Roman RS, Smith J, Walker M, Byrne S, Ramotar K, Dyck B, et al. Rapid spread of a methicillin-resistant *Staphylococcus aureus* strain. Clin Infect Dis. 1997;25:698–705. DOI: 10.1086/513758

8. Liassine N, Auckenthaler R, Descombres M-C, Bes M, Vandenesch F, Etienne J. Community-acquired methicillin-resistant *Staphylococcus aureus* isolated in Switzerland contains the Panton-Valentine leukocidin or exfoliative toxin genes. J Clin Microbiol. 2004;42:825–8. DOI: 10.1128/JCM.42.2.825-828.2004

9. Krziwanek K, Luger C, Sammer B, Stumvoll S, Stammler M, Sagel U, et al. MRSA in Austria: an overview. Clin Microbiol Infect. 2008;14:250–9. DOI: 10.1111/j.1469-0691.2007.01896.x

10. Maijer J, Mehl H, Reischl U, Drabel I, Witte W, Luhn N, et al. Panton-Valentine leukocidin-positive methicillin-resistant *Staphylococcus aureus* in Germany associated with travel or foreign family origin. Eur J Clin Microbiol Infect Dis. 2005;24:637–9. DOI: 10.1007/s10096-005-0008-8

11. Larsen AR, Böcher S, Stegger M, Goering R, Pallesen LV, Skov R. Epidemiology of the European Community associated methicillin-resistant *Staphylococcus aureus* (CC80-MRSAIV) in Denmark 1994–2004. J Clin Microbiol. 2008;46:62–8. DOI: 10.1128/JCM.01381-07

12. Kaiser AM, Schultz C, Kruthof GI, Debets-Ossenkopp Y, Vandebroucke-Grauls C. Carriage of resistant microorganisms in repatriates from foreign hospitals to the Netherlands. Clin Microbiol Infect. 2004;10:972–9. DOI: 10.1111.j.1469-0691.2004.01000.x

13. Fischer D, Veldman A, Diepemach H, Schäfer V. Bacterial colonization of patients undergoing international air transport: a prospective epidemiologic study. J Travel Med. 2004;11:44–8.

14. Gustafsson EB, Remberg H, Johansson PS. MRSA in children from foreign countries adopted to Swedish families. Acta Paediatr. 2007;96:105–8. DOI: 10.1111/j.1651-2227.2007.00996.x

15. Stenhem M, Ortvist A, Ringberg H, Larsson L, Olsson-Liljequist B, Haeggman S, et al.; Swedish Study Group on MRSA Epidemiology. Epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) in Sweden 2000–2003, increasing incidence and regional differences. BMC Infect Dis. 2006;6:30. DOI: 10.1186/1471-2334-6-30

16. Stenhem M, Ortvist A, Ringberg H, Larsson L, Olsson-Liljequist B, Haeggman S, et al.; Swedish Study Group on MRSA Epidemiology. Validity of routine surveillance data: a case study on Swedish notifications of methicillin-resistant *Staphylococcus aureus*. Euro Surveill. 2009;14:19281.

17. Swedish Travel and Tourist Data Base [database on the internet] [cited 2009 Nov 17]. http://www.resursab.se

18. Statistics Sweden [database on the internet] [cited 2009 Nov 17]. http://www.scb.se

19. Swedish Intercountry Adoptions Authority (MIA) [database on the internet] [cited 2009 Nov 17]. http://www.mia.eu

20. Smyth RW, Kahlmeter G, Olsson Liljequist B, Hoffman B. Methods for identifying methicillin-resistant *Staphylococcus aureus*. J Hosp Infect. 2001;48:103–7. DOI: 10.1053/jhin.2001.0933

21. Murchan S, Kaufman ME, Deplano A, de Ryck R, Struelens M, Zinn CE, et al. Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant *Staphylococcus aureus*: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J Clin Microbiol. 2003;41:1574–85. DOI: 10.1128/JCM.41.4.1574-1585.2003

22. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. J Clin Microbiol. 2000;38:1008–15.

23. Helgason KO, Jones ME, Edwards G. Panton-Valentine leukocidin-positive *Staphylococcus aureus* and foreign travel. J Clin Microbiol. 2008;46:832–3. DOI: 10.1128/JCM.02154-07

24. Denis O, Deplano A, De Beenhouwer H, Hallin M, Huysmans G, Garrino MG, et al. Polychronal emergence and importation of community-acquired methicillin-resistant *Staphylococcus aureus* strains harbouring Panton-Valentine leukocidin genes in Belgium. J Antimicrob Chemother. 2005;56:1103–6. DOI: 10.1093/jac/dki379

25. Urth T, Juul G, Skov R, Schonheyder HC. Spread of methicillin-resistant *Staphylococcus aureus* ST80-IV clone in a Danish community. Infect Control Hosp Epidemiol. 2005;26:144–9. DOI: 10.1086/502518

26. Tiemersma EW, Bronzaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N, et al.; European Antimicrobial Resistance Surveillance System Participants. Methicillin-resistant *Staphylococcus aureus* in Europe 1999–2002. Emerg Infect Dis. 2004;10:1627–34.

27. Diekema DJ, Pfäffer MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al.; the SENTRY Participants Group. Survey of infections due to *Staphylococcus aureus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis. 2001;32(Suppl 2):S114–32. DOI: 10.1086/320184

28. Zinn CS, Westh H, Rosdahl VT, and the SARISA Study Group. An international multicenter study of antimicrobial resistance and typing of hospital *Staphylococcus aureus* isolates from 21 laboratories in 19 countries or states. Microb Drug Resist. 2004;10:160–8. DOI: 10.1089/1076629041310055

29. Borg MA, de Kraker M, Siciliana E, van de Sande-Bruinsma N, Tiermersma E, Monen J, et al., on behalf of the ARMed Project members and collaborators. Prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) in invasive isolates from southern and eastern Mediterranean countries. J Antimicrob Chemother. 2007;60:1310–5. DOI: 10.1093/jac/dkm365

30. Ekdahl K, Giesecke J. Travellers returning to Sweden as sentinels for comparative disease incidence in other European countries, *Campylobacter* and *Giardia* infection as examples. Euro Surveill. 2004;9:6–9.

31. Askling HH, Nilsson J, Tegnell A, Janzon R, Ekdahl K. Malaria risk in travelers. Emerg Infect Dis. 2005;11:436–41.

32. Enright MC, Day NPJ, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. J Clin Microbiol. 2000;38:1008–15.

33. Feil EJ, Nickerson EK, Chantratita N, Wuthiekanun V, Srismong R, Cousins R, et al. Rapid detection of the pandemic methicillin-resistant *Staphylococcus aureus* clone ST239 and its dominance in Asian hospitals. J Clin Microbiol. 2008;46:1520–2. DOI: 10.1128/JCM.02238-07

34. Ko KS, Lee J-Y, Suh JY, Oh WS, Peck KR, Lee NY, et al. Distribution of major genotypes among methicillin-resistant *Staphylococcus aureus* clones in Asian countries. J Clin Microbiol. 2005;43:421–6. DOI: 10.1128/JCM.43.1.421-426.2005
35. Aires de Sousa M, Bartzavali C, Spiliopoulou I, Santos Sanches I, Crisóstomo MI, de Lencastre H. International methicillin-resistant Staphylococcus aureus clones endemic in a university hospital in Patras Greece. J Clin Microbiol. 2003;41:2027–32. DOI: 10.1128/JCM.41.5.2027-2032.2003

36. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003;9:978–84.

37. Mato R, Campanile F, Stefani S, Crisóstomo MI, Santagati M, Sanches SI, et al. Clonal types and multidrug resistance patterns of methicillin-resistant Staphylococcus aureus (MRSA) recovered in Italy during the 1990s. Microb Drug Resist. 2004;10:106–13. DOI: 10.1089/1076629041310109

38. Wisplinghoff H, Ewertz B, Wisplinghoff S, Stefanik D, Plum G, Perdreau-Remington F, et al. Molecular evolution of methicillin-resistant Staphylococcus aureus in the metropolitan area of Cologne, Germany, from 1984 to 1998. J Clin Microbiol. 2005;43:5445–51. DOI: 10.1128/JCM.43.11.5445-5451.2005

39. Kim ES, Song JS, Lee HJ, Choe PG, Park KH, Cho JH, et al. A survey of community-associated methicillin-resistant Staphylococcus aureus in Korea. J Antimicrob Chemother. 2007;60:1108–14. DOI: 10.1093/jac/dkm309

40. Ko KS, Lee J-Y, Bek KY, Peck KR, Rhee JY, Kwon KT, et al. Characterization of Staphylococcus aureus nasal carriage from children attending an outpatient clinic in Seoul, Korea. Microb Drug Resist. 2008;14:37–44. DOI: 10.1089/mdr.2008.0776

Address for correspondence: Mikael Stenhem, Department of Epidemiology, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden; email: mikael.stenhem@smi.se

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.
| ST   | Sub-Saharan Africa | UK and Ireland | East Asia | Central and Eastern Europe | North Africa, Israel, Arabic countries, Iran | North America | Northeastern Mediterranean | Nordic and Pacific islands | South America | Southern Europe | Western Europe | Total HA:CA (%, 95% CI) | Total |
|------|-------------------|----------------|-----------|----------------------------|---------------------------------------------|--------------|---------------------------|---------------------------|----------------|----------------|---------------|--------------------------|-------|
| ST1  |                   |                |           |                            |                                             |              |                           |                           |                |                |               | 3 (27, 6–61)                 | 11    |
| HA   | 2                 | 1              |           |                            |                                             |              |                           |                           |                |                |               |                          |       |
| CA   | 3                 | 1              |           |                            |                                             |              |                           |                           |                |                |               | 4 (36, 11–69)                 |       |
| ST5  |                   |                |           | 9                          | 2                                           |              |                           |                           |                |                |               | 16 (67, 45–84)               | 24    |
| HA   | 1                 | 1              |           |                            |                                             |              |                           |                           |                |                |               | 1 (17, 5–37)                  |       |
| CA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               |                          |       |
| ST8  |                   | 1              | 1         | 4                          | 1                                           |              |                           |                           |                |                |               | 12 (39, 22–58)               | 31    |
| HA   | 1                 | 1              | 1         |                            |                                             |              |                           |                           |                |                |               | 1 (8, 1–27)                   |       |
| CA   | 1                 | 4              | 5         |                            |                                             |              |                           |                           |                |                |               | 3 (45, 27–64)                |       |
| ST22 |                   | 15             | 1         |                            | 1                                           | 1            |                           |                           |                |                |               | 21 (88, 68–97)              | 24    |
| HA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               |                          |       |
| CA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               | 2 (8, 1–27)                   |       |
| ST30 |                   | 1              | 1         |                            | 1                                           | 3            |                           |                           |                |                |               | 5 (18, 6–37)                | 28    |
| HA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               | 1 (18, 2–52)                 |       |
| CA   | 13                | 2              | 2         |                            |                                             |              |                           |                           |                |                |               | 19 (68, 48–84)               |       |
| ST36 |                   | 1              | 1         | 4                          | 1                                           | 1            |                           |                           |                |                |               | 20 (95, 76–100)             | 21    |
| HA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               | 1 (2, 0–3)                   |       |
| CA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               |                          |       |
| ST45 |                   | 1              | 1         | 1                          |                                             |              |                           |                           |                |                |               | 6 (55, 23–83)               | 11    |
| HA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               | 2 (18, 2–52)                 |       |
| CA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               |                          |       |
| ST72 |                   | 2              |           |                            |                                             |              |                           |                           |                |                |               | 2 (25, 3–65)                | 8     |
| HA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               | 2 (75, 35–97)                |       |
| CA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               |                          |       |
| ST80 |                   | 1              | 2         |                            | 1                                           | 1            |                           |                           |                |                |               | 5 (8, 3–19)                  | 59    |
| HA   |                   |                |           |                            |                                             |              |                           |                           |                |                |               | 2 (78, 48–84)                |       |
| CA   | 2                 | 2              | 2         | 18                          | 21                                          | 1            |                           |                           |                |                |               |                          |       |
| HA  | CA     | 1   | 1 (20, 0.5–72) | 5   |
|-----|--------|-----|----------------|-----|
|     | 3      | 1   | 4 (80, 28–99)  | 7   |
| ST125 |       | 1   | 5   | 6 (75, 35–97) | 8   |
|     | 0      |     |     | 2 (33, 4–78)  |     |
| ST128 |       | 1   | 5   | 11 (95, 74–100) | 19  |
|     | 0      |     |     | 2 (2, 0.04–8) |     |
| ST239 |       | 22  | 5   | 30  | 3   | 61 (94, 85–98) | 65  |
|     | 1      |     |     | 1   | 1   | 1 (92, 62–100) | 12  |
| Total HA:CA (%, 95% CI) | | 18  | 33  | 92  | 24  | 50  | 24  | 90  | 1   | 14  | 12  | 36  | 18  | 414 |

*Shown are 414 independent cases (not belonging to the same transmission chain) of 444 cases acquired abroad. Cases are stratified as healthcare-acquired (HA) and community-acquired (CA) for each sequence type (ST) and region of acquisition. In some instances, numbers in rows and columns do not add up to the totals because of persons with STs other than the ones listed or because cases were indeterminable with regard to transmission setting. CI, confidence interval.